Rina Kawano
Overview
Explore the profile of Rina Kawano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
35
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kawano R, Haze T, Fujiwara A, Haruna A, Ozawa M, Kobayashi Y, et al.
Clin Exp Nephrol
. 2024 Jul;
28(12):1282-1289.
PMID: 38970649
Background: Renoprotective effects of sodium glucose transporter 2 (SGLT2) inhibitors, including dapagliflozin, were observed in randomized controlled trials (RCTs). The suspected underlying mechanism is a correction of hyperfiltration, observed as...
2.
Kobayashi Y, Yatsu K, Haruna A, Kawano R, Ozawa M, Haze T, et al.
J Clin Hypertens (Greenwich)
. 2024 Mar;
26(4):355-362.
PMID: 38430457
Single-nucleotide polymorphisms (SNP) of ATP2B1 gene are associated with essential hypertension but their association with resistant hypertension (RHT) remains unexplored. The authors examined the relationship between ATP2B1 SNPs and RHT...
3.
Kobayashi Y, Fujikawa T, Haruna A, Kawano R, Ozawa M, Haze T, et al.
Medicina (Kaunas)
. 2024 Jan;
60(1).
PMID: 38256336
Omega-3 fatty acids have potent lipid-lowering and antiplatelet effects; however, randomized controlled trials have yet to examine the effect of high-dose omega-3 fatty acid administration on peripheral artery disease (PAD)...
4.
Haze T, Kawano R, Takase H, Suzuki S, Hirawa N, Tamura K
Int J Med Inform
. 2023 Nov;
180:105283.
PMID: 37931432
Objectives: Although ChatGPT was not developed for medical use, there is growing interest in its use in medical fields. Understanding its capabilities and precautions for its use in the medical...
5.
Haze T, Ozawa M, Kawano R, Haruna A, Ohki Y, Suzuki S, et al.
Hypertens Res
. 2023 Feb;
46(5):1132-1144.
PMID: 36754972
Primary aldosteronism is the most frequent secondary hypertensive disease and is characterized by an elevated risk for cardiovascular disease. The current standard treatments are adrenalectomy and/or administration of mineralocorticoid receptor...
6.
Ozawa M, Hirawa N, Haze T, Haruna A, Kawano R, Komiya S, et al.
Clin Exp Nephrol
. 2022 Dec;
27(4):365-373.
PMID: 36574105
Background: Chronic kidney disease-mineral and bone disorder (CKD-MBD), nutritional status, and uremia management have been emphasized for bone management in hemodialysis patients. Nevertheless, valuable data on the importance of muscle...
7.
Komiya S, Katsumata M, Ozawa M, Haze T, Kawano R, Ohki Y, et al.
Clin Exp Nephrol
. 2022 Apr;
26(9):851-858.
PMID: 35471469
Background: Tolvaptan (TLV) is reported to improve diuretic effects in patients with chronic kidney disease (CKD) when furosemide (FUR) is not sufficiently effective. However, it is not clear whether TLV...
8.
Haze T, Hatakeyama M, Komiya S, Kawano R, Ohki Y, Suzuki S, et al.
Hypertens Res
. 2021 Aug;
44(10):1341-1351.
PMID: 34363052
Patients with primary aldosteronism have a higher risk of chronic kidney disease. Visceral fat tissue is hypothesized to stimulate the adrenal glands to overproduce aldosterone, and aldosterone promotes visceral fat...